Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial
- aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA
- Professor N J Talley, Department of Medicine, University of Sydney, Nepean Hospital, PO Box 63, Penrith NSW 2751, Australia.
- Accepted 5 December 2000
INTRODUCTION Erythromycin, a motilin agonist, is a potent prokinetic. ABT-229 is a specific motilin agonist that dose dependently accelerates gastric emptying. Dyspepsia and gastroparesis are common problems in type 1 diabetes mellitus. We aimed to evaluate the efficacy of ABT-229 in symptomatic diabetic patients with and without delayed gastric emptying.
METHODS Patients with type 1 diabetes and postprandial symptoms were randomised (n=270). Based on a validated C13 octanoic acid breath test, patients were assigned to either the delayed or normal gastric emptying strata. Patients received one of four doses of ABT-229 (1.25, 2.5, 5, or 10 mg twice daily before breakfast and dinner) or placebo for four weeks following a two week baseline. A self report questionnaire measured symptoms on visual analogue scales; the primary outcome was assessment of change in the total upper abdominal symptom severity score (range 0–800 mm) from baseline to the final visit.
RESULTS The treatment arms were similar regarding baseline characteristics. There was symptom improvement on placebo and a similar level of improvement on active therapy for the upper abdominal discomfort severity score (mean change from baseline −169, −101, −155, −143, and −138 mm for placebo, and 1.25, 2.5, 5, and 10 mg ABT-229, respectively, at four weeks by intent to treat). The results were not significantly different in those with and without delayed gastric emptying. The severity of bloating, postprandial nausea, epigastric discomfort, heartburn, and acid regurgitation worsened dose dependently in a greater number of patients receiving ABT-229 than placebo. Overall, 63% of patients on placebo reported a good or excellent global response, and this was not different from the active treatment arms.
CONCLUSIONS The motilin agonist ABT-229 was not efficacious in the relief of postprandial symptoms in diabetes mellitus in the presence or absence of delayed gastric emptying.
- Abbreviations used in this paper:
- glycated haemoglobin